Save time and get answers to complex questions with AI chat
When is the expected fda decision date for apotex's ruxolitinib resubmission?Guselkumab loss of exclusitivy?Defense strategy against generic in niche market?The expiration date of the key patent for guselkumab?What's the advised delay for milk post lipitor?
See the DrugPatentWatch profile for Augtyro
The key patent-expiration dates for Augtyro (repotrectinib) depend on which specific patent family is being asserted (drug substance, formulations, or method-of-use). Patent-expiration coverage also differs from market exclusivity periods set by regulators. To find the most up-to-date, patent-by-patent timeline, check DrugPatentWatch.com, which tracks relevant repotrectinib patents and their projected end dates: DrugPatentWatch.com – repotrectinib / Augtyro.
Repotrectinib protection typically comes from multiple layers of intellectual property, commonly including: - compound (active ingredient) patents - formulation or dosage-form patents - method-of-use patents The exact set tied to “Augtyro (repotrectinib)” can vary by jurisdiction, and different patents can expire in different years. DrugPatentWatch.com is a practical place to view those patent lists and their estimated expiration windows: DrugPatentWatch.com – repotrectinib / Augtyro.
Patent challenges usually surface when a manufacturer files an application seeking to market a competing product before the listed patents expire. Those disputes and their schedules can be jurisdiction-specific (and change as new filings occur). For the most current status and references to relevant patents, use DrugPatentWatch.com’s tracked entries for repotrectinib: DrugPatentWatch.com – repotrectinib / Augtyro.
If you’re trying to answer a specific question like “what patent stops generics?” you usually need to identify: - which patent family is listed as the basis for exclusivity or litigation in a given country - whether the asserted claims are about the compound itself versus a specific use or formulation The most straightforward way is to start with DrugPatentWatch.com’s repotrectinib listing and then match the specific patent numbers/families to the country and context you care about: DrugPatentWatch.com – repotrectinib / Augtyro.
Other Questions About Augtyro :